Features, predictors and prognosis of lymphoproliferative disorders post-liver transplantation regarding disease presentation time: Report from the PTLD.Int.survey

Annals of Transplantation

Volumn 16, Issue 1, 2011, Pages 39-47

  Izadi, Morteza ^a   Taheri, Saeed ^b  

^a BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Dr Taheri Medical Research Group   (Iran)

Author keywords

Early onset; Late onset; Liver transplantation adverse effects; Post transplant lymphoproliferative disorders

Indexed keywords

ANTINEOPLASTIC AGENT; AZATHIOPRINE; CYCLOSPORIN; LYMPHOCYTE ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; THYMOCYTE ANTIBODY;

ARTICLE; CLINICAL FEATURE; DISEASE COURSE; EPSTEIN BARR VIRUS INFECTION; GRAFT RECIPIENT; GRAFT SURVIVAL; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER GRAFT; LIVER TRANSPLANTATION; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; POSTTRANSPLANTATION LYMPHOPROLIFERATIVE DISEASE; PROGNOSIS;

ADOLESCENT; ADULT; CHILD; DATA COLLECTION; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LINEAR MODELS; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; PROGNOSIS; RISK FACTORS; TIME FACTORS; YOUNG ADULT;

EID: 79953286593     PISSN: 14259524     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (72)

1. Frank D, Cesarman E, Liu YF et al: Posttransplantation lymphoproliferative disorders frequently contain type A and not type B Epstein-Barr virus. Blood, 1995; 85: 1396-403
2. Nalesnik MA, Jaffe R, Starzl TE et al: The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol, 1988; 133: 173-92
3. Khedmat H, Alavian SM, Taheri S: Significance of Epstein-Barr virus infection in the outcome of renal transplant patients with lymphoproliferative disorders. Ann Transplant, 2010; 15(2): 40-44
4. Swerdlow SH: Classification of the posttransplant lymphoproliferative disorders: from the past to the present. Semin Diagn Pathol, 1997; 14: 2-7
5. Opelz G, Schwarz V. Wujciak T et al: Analysis of non-Hodgkin's lymphomas in organ transplant recipients. Transplant Rev, 1995: 9: 231-240
6. Mamzer-Bruneel MF, Bourquelot P, Hermine O et al: Treatment and prognosis of post-transplant lymphoproliferative disease. Ann Transplant, 1997; 2: 42-48
7. Boubenider S, Hiesse C, Goupy C et al: Incidence and consequences of posttransplantation lymphoproliferative disorders. J Nephrol, 1997; 10: 136-145
8. Swinnen LJ: Diagnosis and treatment of transplantrelated lymphoma. Ann Oncol, 2000; 11: 45-48
9. Domingo Domenech E, De San Jose S, Gonzalez- Barca E et al: Post-transplant lymphomas: a 20 year epidemiologic, clinical and pathologic study in a single center. Haematologic, 2001; 86: 715
10. Khedmat H, Taheri S: Characteristics and Prognosis of Post Transplantation Lymphoproliferative Disorders within Renal Allograft: Report from PTLDint Survey. Ann Transplant, 2010; 15(3): 80-86
11. Izadi M, Taheri S: Significance of in Situ Hybridization Results for EBV-Encoded RNA in Post Transplantation Lymphoproliferative Disorder Setting: Report from the PTLDint Survey. Ann Transplant, (accepted).
12. Jain A, Nalesnik M, Reyes J et al: Post-transplant lymphoproliferative disorders in liver transplantation: a 20-year experience. Ann Surg, 2002; 236: 429
13. Smets F, Vajro P, Cornu G et al: Indications and results of chemotherapy in children with post-transplant lymphoproliferative disease after liver transplantation. Transplantation, 2000; 69: 982
14. Guthery SL, Heubi JE, Bucuvalas JC et al: Determination of risk factors for EBV-associated posttransplant lymphoproliferative disorders in pediatric liver transplant recipients using objective case ascertainment. Transplantation, 2003; 75: 987
15. Newell KA, Alonso EM, Kelly SM et al: Association between liver transplantation for Langerhans cell histiocytosis, rejection, and development of posttransplant lymphoproliferative disease in children. J Pediatr, 1997; 131: 98
16. Khedmat H, Taheri S: Late onset post transplantation lymphoproliferative disorders: analysis of international data from 5 studies. Ann Transplant, 2009; 14(4): 80-85
17. Khedmat H, Taheri S: Early onset post transplantation lymphoproliferative disorders: analysis of international data from 5 studies. Ann Transplant, 2009; 14(3): 74-77
18. Poirel HA, Bernheim A, Schneider A: Characteristic Pattern of Chromosomal Imbalances in Posttransplantation Lymphoproliferative Disorders: Correlation with Histopathological Subcategories and EBV Status. Transplantation, 2005; 80(2): 176-184
19. Opelz G, Dohler B: Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant, 2004; 4: 222-230
20. Kremers WK, Devarbhavi HC, Wiesner RH et al: Post-transplant lymphoproliferative disorders following liver transplantation: incidence, risk factors and survival. Am J Transpl, 2006; 6: 1017-1024
21. Leblond V, Davi F, Charlotte F et al: Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity? J Clin Oncol, 1998; 16: 2052-2059
22. Leblond V, Choquet S: Lymphoproliferative disorders after liver transplantation. J Hepatol, 2004; 40: 728-735
23. Ruiz P, Garcia M, Nicolas M et al: Lymphoplasmacytic hyperplasia (possibly pre-PTLD) has varied expression and appearance in intestinal transplant recipients receiving Campath immunosuppression. Transplant Proc, 2004; 2: 386-387
24. Cockfield SM, Preiksaitis JK, Jewell LD, Parfrey NA: Post-transplant lymphoproliferative disorder in renal allograft recipients. Clinical experience and risk factor analysis in a single center. Transplantation, 1993; 56: 88-96
25. Hanto DW, Gajl-Peczalska KJ, Frizzera G et al: Epstein- Barr virus (EBV) induced polyclonal and monoclonal B-cell lymphoproliferative diseases occurring after renal transplantation. Ann Surg, 1983; 198: 356
26. Harris KM, Schwartz ML, Slasky BS et al: Posttransplantation cyclosporine-induced lymphoproliferative disorders: clinical and radiologic manifestations. Radiology, 1987; 162: 697
27. Dotti G, Fiocchi R, Motta T et al: Lymphoma occurring late after solid organ transplantation: influence of treatment on the clinical outcome. Transplantation, 2002: 74: 1095
28. Nuckols JD, Baron PW, Stenzel TT et al: The pathology of liver-localized post-transplant lymphoproliferative disease: A report of three cases and a review of the literature. Am J Surg Pathol, 2000; 24: 733-741
29. Limaye AP, Huang ML, Atienza EE et al: Detection of Epstein-Barr virus DNA in sera from transplant recipients with lymphoproliferative disorders. J Clin Microbiol, 1999; 37: 1113
30. Ziarkiewicz-Wroblewska B, Gornicka B, Suleiman W et al: Posttransplant lymphoproliferative disorder: Morphological picture and diagnostic difficulties. Transplant Proc, 2006; 38: 168
31. Wu JF, Ho MC, Ni YH et al: Timing of Epstein-Barr Virus Acquisition and the Course of Posttransplantation Lymphoproliferative Disorder in Children. Transplantation, 2009; 87(5): 758-762
32. Limaye AP, Huang ML, Atienza EE et al: Detection of Epstein-Barr Virus DNA in Sera from Transplant Recipients with Lymphoproliferative Disorders. J Clin Microbiol, 1999; 37(4): 1113-1116
33. Lorenzini S, Andreone P, Gramenzi A et al: Posttransplant lymphoproliferative disorders in liver transplanted patients: a report of four cases. Transplant Proc, 2006; 38: 1477-1480
34. Timms JM, Bell A, Flavell JR et al: Target cells of Epstein-Barr virus (EBV)-positive post-transplant lymphoproliferative disease: similarities to EBVpositive Hodgkin's lymphoma. Lancet, 2003; 361: 217-223
35. Collins MH, Montone KT, Leahey AM et al: Posttransplant lymphoproliferative disease in children. Pediatr Transplant, 2001; 5: 250-257
36. Buadi FK, Heyman MR, Gocke CD et al: Treatment and outcomes of post-transplant lymphoproliferative disease: a single institution study. Am J Hematol, 2007; 82(3): 208-214
37. Kerkar N, Morotti RA, Madan RP et al: The changing face of post-transplant lymphoproliferative disease in the era of molecular EBV monitoring. Pediatr Transplant, 2010; 14(4): 504-511
38. Djokic M, Le Beau MM, Swinnen LJ et al: Posttransplant lymphoproliferative disorder subtypes correlate with different recurring chromosomal abnormalities. Genes Chromosomes Cancer, 2006; 45(3): 313-318
39. Dusenbery D, Nalesnik MA, Locker J, Swerdlow SH: Cytologic features of post-transplant lymphoproliferative disorder. Diagn Cytopathol, 1997; 16(6): 489-496
40. Ben-Ari Z, Amlot P, Lachmanan S et al: Posttransplant lymphoproliferative disorder in liver recipients: characteristics, management, and outcome. Liver Transpl Surg, 1999; 5: 184-191
41. Rohrbach JM, Kröber SM, Teufel T et al: EBV-induced polymorphic lymphoproliferative disorder of the iris after heart transplantation. Graefes Arch Clin Exp Ophthalmol, 2004; 242(1): 44-50
42. Praghakaran K, Wise B, Chen A et al: Rational management of posttransplant lymphoproliferative disorder in pediatric recipients. J Pediatr Surg, 1999: 34: 112-116
43. Gerstenkorn C, Jackson G, Di Franco F et al: Outcome of PTLD in renal and liver allograft recipients. Transplant Proc, 2001; 33(4): 2469-2472
44. Norin S, Kimby E, Ericzon BG et al: Posttransplant lymphoma - a single-center experience of 500 liver transplantations. Med Oncol, 2004; 21(3): 273-284
45. Capello D, Cerri M, Muti G et al: Molecular histogenesis of posttransplantation lymphoproliferative disorders. Blood, 2003; 102: 3775-3785
46. Riddler SA, Breinig MC, McKnight JL: Increased Levels of Circulating Epstein-Barr Virus (EBV)-Infected Lymphocytes and Decreased EBV Nuclear Antigen Antibody Responses Are Associated With the Development of Posttransplant Lymphoproliferative Disease in Solid-Organ Transplant Recipients. Blood, 1994; 84(3): 972-984
47. Muti G, Cantoni S, Oreste P et al: Post-transplant lympoproliferative disorders: improved outcome after clinico-pathologically tailored treatment. Haematologica, 2002; 87: 67-77
48. Castellano-Sanchez AA, Li S, Qian J et al: Primary central nervous system post-transplant lymphoproliferative disorders. Am J Clin Pathol, 2004; 121: 246-253
49. Wilde GE, Moore DJ, Bellah RD: Posttransplantation lymphoproliferative disorder in pediatric recipients of solid organ transplants: timing and location of disease. AJR Am J Roentgenol, 2005; 185(5): 1335-1341
50. Trappe R, Riess H, Babel N: Salvage Chemotherapy for Refractory and Relapsed Posttransplant Lymphoproliferative Disorders (PTLD) After Treatment With Single-Agent Rituximab. Transplantation, 2007; 83(7): 912-918
51. Jain A, Nalesnik M, Reyes J et al: Post-transplant lymphoproliferative disorders in liver transplantation: a 20-year experience. Ann Surg, 2002; 236: 429
52. Doria C, Marino IR, Scott VL et al: Posttransplant lymphoproliferative disorders presenting at sites of previous surgical intervention. Transplantation, 2003; 75: 1066
53. Duvoux C, Pageaux GP, Vanlemmens C et al: Risk factors for lymphoproliferative disorders after liver transplantation in adults: an analysis or 480 patients. Transplantation, 2002; 74: 1103
54. Schaar CG, van der Pijl JW, van Hoek B et al: Successful outcome with a quintuple approach of posttransplant lympho-proliferative disorders. Transplantation, 2001: 71: 47
55. Tsai DE, Hardy CL, Tomaszewski JE et al: Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term followup of 42 adult patients. Transplantation, 2001: 71: 1076
56. Avolio AW, Agnes S, Barbarino R: Posttransplant Lymphoproliferative Disorders After Liver Transplantation: Analysis of Early and Late Cases in a 255 Patient Series. Transplant Proc, 2007; 39(6): 1956-1960
57. Halaburda K, Nasiłowska-Adamska B, Grabarczyk P et al: Limited predictive value of real-time quantitative PCR cytomegalovirus monitoring in the blood. Fatal CMV pneumonia in an autologous stem cell transplant recipient previously treated with alemtuzumab. Ann Transplant, 2007; 12(2): 37-40
58. Montone KT, Litzky LA, Wurster A et al: Analysis of Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after lung transplantation. Surgery, 1996; 119: 544-551
59. Benkerrou M, Durandy A, Fischer A: Therapy for transplant-related lymphoproliferative disease. Hematol Oncol Clin North Am, 1993; 7: 467-475
60. Basgoz N, Preiksaitis JK: Post-transplant lymphoproliferative disorder. Infect Dis Clin North Am, 1995; 9: 901-923
61. Riddler SA, Breinig MC, McKnight JL: Increased levels of circulating EBV-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid organ transplant recipients. Blood, 1994; 3: 972-984
62. Walker RC, Paya CV, Marshall WF et al: Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for post-transplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations. J Heart Lung Transplant, 1995; 14: 214-221
63. Reynders CS, Whitman GJ, Chew FS: Posttransplant lymphoproliferative disorder of the lung. AJR Am J Roentgenol, 1995; 14: 214-221
64. Yousem SA, Randhawa R, Locker J: Posttransplant lymphoproliferative disorders in heart-lung transplant recipients: primary presentation in the allograft. Hum Pathol, 1989; 20: 361-369
65. Douglas RS, Goldstein SM, Katowitz JA et al: Orbital presentation of post-transplantation lymphoproliferative disorder: a small case series. Ophthalmology, 2002; 109: 2351-2355
66. Sheil AG: Patterns of malignancies following renal transplantation. Transplant Proc, 1999; 31: 1263-1265
67. Smith JM, Rudser K, Gillen D et al: Risk of lymphoma after renal transplantation varies with time: An analysis of the United States Renal Data System. Transplantation, 2006; 81: 175
68. Shahinian VB, Muirhead N, Jevnikar AM et al: Epstein- Barr virus seronegativity is a risk factor for late-onset posttransplant lymphoproliferative disorder in adult renal allograft recipients. Transplantation, 2003; 75: 851
69. Leblond V, Sutton L, Dorent R et al: Lymphoproliferative disorders after organ transplantation: A report of 24 cases observed in a single center. J Clin Oncol, 1995; 13: 961-968
70. Armitage J, Kormos R, Stuart R: Posttransplant lymphoproliferative disease in thoracic organ transplant patients: 10 years of cyclosporine-based immunosuppression. J Heart Lung Transplant, 1991; 10: 877-887
71. Harris NL, Ferry JA, Swerdlow SH: Posttransplant lymphoproliferative disorders: Summary of society for hematopathology workshop. Semin Diagn Pathol, 1997; 14: 8-14
72. Leblond V, Davi F, Charlotte F et al: Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: A distinct entity? J Clin Oncol, 1998; 16: 2052-2059